Advanced search
Publication Cover
Expert Opinion on Therapeutic Targets Volume 11, 2007 - Issue 11
Submit an article Journal homepage
222
Views
11
CrossRef citations to date
0
Altmetric
Review

Macrophage peroxisome proliferator activated receptor γ as a therapeutic target to combat Type 2 diabetes

Gabriel Pascual University of California, Department of Cellular Molecular Medicine, La Jolla, San Diego, California 92093, USA
,
Mercedes Ricote Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain
&
Andrea L Hevener Assistant Professor University of California, Los Angeles, David Geffen School of Medicine, Division of Endocrinology, Diabetes, and Hypertension, 900 Veteran Avenue, STE 24-130, Los Angeles, CA 90095-7073, USA +1 310 794 7555; +1 310 794 7654; [email protected]
, PhD
Pages 1503-1520 | Published online: 26 Oct 2007

Bibliography

  • DEFRONZO RA, BONADONNA RC, FERRANNINI E: Pathogenesis of NIDDM: a balanced overview. Diabetes Care (1992) 15:318-368.
  • REAVEN GM: Role of insulin resistance in human disease (syndrome X): an expanded definition. Annu. Rev. Med. (1993) 44:121-131.
  • MIRANDA PJ, DEFRONZO RA, CALIFF RM, GUYTON JR: Metabolic syndrome: definition, pathophysiology, and mechanisms. Am. Heart J. (2005) 149:33-45.
  • KAHN BB, FLIER JS: Obesity and insulin resistance. J. Clin. Invest. (2000) 106:473-481.
  • FORD ES, GILES WH, MOKDAD AH: Increasing prevalence of the metabolic syndrome among US adults. Diabetes Care (2004) 27(10):2444-2449.
  • WELLEN KE, HOTAMISLIGIL GS: Inflammation, stress, and diabetes. J. Clin. Invest. (2005) 115:1111-1119.
  • GRIMBLE RF: Inflammatory status and insulin resistance. Curr. Opin. Clin. Nutr. Metab. (2002) 5:551-559.
  • LIBBY P: Inflammation and atherosclerosis. Nature (2002) 420(6917):868-874.
  • SWIRSKI FK, PITTET MJ, KIRCHER MF et al.: Monocyte accumulation in mouse atherogenesis is progressive and proportional to extent of disease. Proc. Natl. Acad. Sci. (2006) 103(27):10340-10345.
  • LIN WW, KARIN M: A cytokine-mediated link between innate immunity, inflammation, and cancer. J. Clin. Invest. (2007) 117(5):1175-1183.
  • VENTRE J, DOEBBER T, WU M et al.: Targeted disruption of the TNF-α gene: metabolic consequences in obese and nonobese mice. Diabetes (1997) 46(9):1526-1531.
  • YUAN M, KONSTANTOPOULOS N, LEE J et al.: Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkβ. Science (2001) 293:1673-1677.
  • HIROSUMI J, TUNCAN G, CHANG L et al.: A central role for JNK in obesity and insulin resistance. Nature (2002) 420:333-336.
  • ARKAN MC, HEVENER AL, GRETEN FR et al.: IKK-β links inflammation to obesity-induced insulin resistance. Nat. Med. (2005) 11:191-198.
  • CAI D, YUAN M, FRANTZ DF et al.: Local and systemic insulin resistance due to hepatic activation of IKK-β and NF-κB. Nat. Med. (2005) 11:183-190.
  • WEISBERG SP, MCCANN D, ROSENBAUM DM, LEIBEL RL, FERRANTE AW: Obesity is associated with macrophage accumulation in adipose tissue. J. Clin. Invest. (2003) 112:1796-1808.
  • XU H, BARNES GT, YANG Q et al.: Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J. Clin. Invest. (2003) 112:1821-1830.
  • HARMEN-BOEHM I, BLUHER M, REDEL H et al.: Macrophage infiltration into omental versus subcutaneous fat across different populations: effect of regional adiposity and the comorbidities of obesity. J. Clin. Endocrinol. Metab. (2007) 92:2240-2247.
  • CANCELLO R, HENEGAR C, VIGUERIE N et al.: Reduction of macrophage infiltration and chemoattractant gene expression changes in white adipose tissue of morbidly obese subjects after surgery-induced weight loss. Diabetes (2005) 54:2277-2286.
  • FISHER-POSOVSZKY P, WABITSCH M, HOCHBERG Z: Endocrinology of adipose tissue – an update. Horm. Metab. Res. (2007) 39:314-321.
  • BOULOUMIE A, CURAT CA, SENGENES C, LOLMEDE K, MIRANVILLE A, BUSSE R: Role of macrophage tissue infiltration in metabolic diseases. Curr. Opin. Clin. Nutr. Metab. Care (2005) 8:347-354.
  • SHOELSON S, LEE J, GOLDFINE AB: Inflammation and insulin resistance. J. Clin. Invest. (2006) 116(7):1793-1801.
  • ELBRECHT A, CHEN Y, CULLINAN CA et al.: Molecular cloning, expression and characterization of the human peroxisome proliferator activated receptor γ1 and γ2. Biochem. Biophys. Res. Commun. (1996) 224:431-437.
  • MUKHERJEE R, JOW L, CROSTON GE, PATERNITI JR: Identification, characterization, and tissue distribution of human peroxisome proliferator-activated receptor (PPAR) isoforms PPARg2 versus PPARg1 and activation with retinoid X receptor agonists and antagonists. J. Biol. Chem. (1997) 272(12):8071-8076.
  • FAJAS L, AUBOEUF D, RASPE E et al.: The organization, promoter analysis, and expression of the human PPARγ gene. J. Biol. Chem. (1997) 272(30):18779-18789.
  • FAJAS L, FRUCHART J-C, AUWERX J: PPARγ3 mRNA: a distinct PPARγ mRNA subtype transcribed from an independent promoter. FEBS Lett. (1998) 438:55-60.
  • KLIEWER SA, FORMAN BM, BLUMBERG B et al.: Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Proc. Natl. Acad. Sci. USA (1994) 91:7355-7359.
  • LOVISCACH M, RAHMAN N, CARTER L et al.: Distribution of peroxisome proliferator activated receptors (PPARs) in human skeletal muscle and adipose tissues: relation to insulin action. Diabetologia (2000) 43:304-311.
  • VIDAL-PUIG AJ, CONSIDINE RV, JIMENEZ-LINAN M et al.: Peroxisome proliferator-activated receptor gene expression in human tissues: effects of obesity, weight loss, and regulation by insulin and glucocorticoids. J. Clin. Invest. (1997) 99:2416-2422.
  • TONTONOZ P, HU E, GRAVES RA, BUDAVARI AI, SPIEGELMAN BM: mPPARγ2: tissue specific regulator of an adipocyte enhancer. Genes Dev. (1994) 8(10):1224-1234.
  • CHAWLA A, SCHWARTZ EJ, DIMACULANGAN DD, LAZAR MA: Peroxisome proliferator-activated receptor (PPAR)γ: adipose-predominant expression and induction early in adipocyte differentiation. Endocrinology (1994) 135:798-800.
  • BARAK Y, NELSON MC, ONG ES et al.: PPARγ is required for placental, cardiac and adipose tissue development. Mol. Cell (1999) 4:585-595.
  • BURANT C, SREENAN S, HIRANO K et al.: Troglitazone action is independent of adipose tissue. J. Clin. Invest. (1997) 100(11):2900-2908.
  • HE W, BARAK Y, HEVENER A et al.: Adipose-specific peroxisome proliferator-activated receptor g knockout causes insulin resistance in fat and liver but not in muscle. Proc. Natl. Acad. Sci. USA (2003) 100:15712-15717.
  • KOUTNIKOVA H, COCK TA, WATANANBE M et al.: Compensation by the muscle limits the metabolic consequences of lipodystrophy in PPARγ hypomorphic mice. Proc. Natl. Acad. Sci. USA (2003) 100(24):14457-14462.
  • HEVENER AL, HE W, BARAK Y et al.: Muscle-specific PPARγ deletion causes insulin resistance. Nat. Med. (2003) 9:1491-1497.
  • NORRIS AW, CHEN L, FISHER SJ et al.: Muscle-specific PPARγ-deficient mice develop increased adiposity and insulin resistance but respond to thiazolidinediones. J. Clin. Invest. (2003) 112:608-618.
  • GAVRILOVA O, HALUZIK M, MATSUSUE K et al.: Liver peroxisome proliferator-activated receptor γ contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass. J. Biol. Chem. (2003) 278:34268-34276.
  • HEVENER A, OLEFSKY J, REICHART D et al.: Macrophage PPARγ is required for normal skeletal muscle and hepatic insulin sensitivity and full antidiabetic effects of thiazolidinediones. J. Clin. Invest. (2007) 117(6):1658-1669.
  • MEDINA-GOMEZ G, VIRTUE S, LELLIOTT C et al.: The link between nutritional status and insulin sensitivity is dependent on the adipocyte-specific peroxisome proliferator-activated receptor-γ2 isoform. Diabetes (1995) 54:1706-1716.
  • ESCHER P, BRAISSANT O, BASU-MODAK S, MICHALIK L, WAHLI W, DESVERGNE B: Rat PPARs: quantitative analysis in adult rat tissues and regulation in fasting and refeeding. Endocrinology (2001) 142:4195-4202.
  • VIDAL-PUIG A, JIMENEZ-LINAN M, LOWELL BB et al.: Regulation of PPARγ gene expression by nutrition and obesity in rodents. J. Clin. Invest. (1996) 97:2553-2561.
  • ALSHULER D, HIRSCHHORN JN, KLANNEMARK M et al.: The common PPARγ Pro12Ala polymorphism is associated with decreased risk of Type 2 diabetes. Nat. Genet. (2000) 26:76-80.
  • MILES PD, BARAK Y, HE W, EVANS RM, OLEFSKY JM: Improved insulin-sensitivity in mice heterozygous for PPAR-γ deficiency. J. Clin. Invest. (2000) 105(3):287-292.
  • KUBOTA N, TERAUCHI Y, MIKI H et al.: PPARγ mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance. Mol. Cell (1999) 4(4):597-609.
  • NOLTE RT, WISELY GB, WESTIN S et al.: Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-γ. Nature (1998) 395:137-143.
  • PERISSI V, ROSENFELD MG: Controlling nuclear receptors: the circular logic of cofactor cycles. Nature Rev. (2005) 6:542-554.
  • McKENNA NJ, XU J, NAWAZ Z, TSAI SY, TSAI M-J, O'MALLEY BW: Nuclear receptor coactivators: multiple enzymes, multiple complexes, multiple functions. J. Steroid Biochem. Molec. Biol. (1999) 69:3-12.
  • ISSEMANN I, PRINCE RA, TUGWOOD JD, GREEN S: The retinoid X receptor enhances the function of the peroxisome proliferator activated receptor. Biochimie (1993) 75:251-256.
  • SCHULMAN IG, SHAO G, HEYMAN RA: Transactivation by retinoid X receptor-peroxisome proliferator-activated receptor γ heterodimers. Mol. Cell Biol. (1998) 18(6):3483-3494.
  • FORMAN BM, TONTONOZ P, CHEN J, BRUN RP, SPIEGELMAN BM, EVANS RM: 15-Deoxy-Δ 12, 14-protaglandin J2 is a ligand for the adipocyte determination factor PPARγ. Cell (1995) 83(5):803-812.
  • KLIEWER SA, LENHARD JM, WILLSON TM, PATEL I, MORRIS DC, LEHMANN JM: A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor γ and promotes adipocyte differentiation. Cell (1995) 83(5):813-819.
  • TONTONOZ P, NAGY L, ALVAREZ JG, THOMAZY VA, EVANS RM: PPARγ promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell (1998) 92(2):241-252.
  • IBRAHIMI A, TEBOUL L, GAILLARD D et al.: Evidence for a common mechanism of action for fatty acids and thiazolidinedione antidiabetic agents on gene expression in preadipose cells. Mol. Pharmacol. (1994) 46:1070-1076.
  • LEHMANN JM, MOORE LB, SMITH-OLIVER TA, WILKINSON WO, WILLSON TM, KLIEWER SA: An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor (PPAR). J. Biol. Chem. (1995) 270:12953-12956.
  • SUTER SL, NOLAN JJ, WALLACE P, GUMBINER B, OLEFSKY JM: Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects. Diabetes Care (1992) 15:193-203.
  • NOLAN JJ, LUDVIK B, BEERDSEN P, JOYCE M, OLEFSKY J: Improvements in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N. Engl. J. Med. (1994) 331:1188-1193.
  • SCHER JU, PILLINGER MH: 15d-PGJ2: the anti-inflammatory prostaglandin? Clin. Immunol. (2005) 114:100-109.
  • NAGY L, SCHWABE JWR: Mechanisms of the nuclear receptor molecular switch. Trends Biochem. Sci. (2004) 29(6):318-324.
  • PICARD F, AUWERX J: PPARg and glucose homeostasis. Ann. Rev. Nutr. (2002) 22:167-197.
  • PERISSI V, AGGARWAL A, GLASS CK, ROSE DW, ROSENFELD MG: A corepressor/coactivator exchange complex required for transcriptional activation by nuclear receptors and other regulated transcription factors. Cell (2004) 116:511-526.
  • CHINETTI G, LESTAVEL S, BOCHER V et al.: PPAR-α and PPAR-γ activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat. Med. (2001) 7:53-58.
  • AKIYAMA TE, SAKAI S, LAMBERT G et al.: Conditional disruption of the peroxisome proliferator-activated receptor γ gene in mice results in lowered expression of ABCA1, ABCG1, and apoE in macrophages and reduced cholesterol efflux. Mol. Cell Biol. (2002) 22:2607-2619.
  • LI A, BROWN K, SILVESTRE M, WILLSON T, PALINSKI W, GLASS C: Peroxisome proliferator-activated receptor γ ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J. CIin. Invest. (2002) 106:523-531.
  • LI AC, BINDER CJ, GUTIERREZ A et al.: Differential inhibition of macrophage foam cell formation and atherosclerosis in mice by PPARα, β/Δ, and γ. J. Clin. Invest. (2004) 114:1564-1576.
  • MOORE KJ, ROSEN ED, FITZGERALD ML et al.: The role of PPAR-γ in macrophage differentiation and cholesterol uptake. Nat. Med. (2001) 7:41-47.
  • CHAWLA A, BOISVERT WA, LEE CH et al.: A PPAR-γ-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol. Cell. (2001) 7:161-171.
  • CHAWLA A, BARAK Y, NAGY L et al.: PPAR-γ dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. Nat. Med. (2001) 7:48-52.
  • RICOTE M, LI AC, WILLSON TM, KELLY CJ, GLASS CK: The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. Nature (1998) 391:79-82.
  • JIANG C, TING AT, SEED B: PPAR-γ agonists inhibit production of monocyte inflammatory cytokines. Nature (1998) 391:82-86.
  • PASCUAL G, FONG AL, OGAWA S et al.: A SUMOylation-dependent pathway mediates transpression of inflammatory response genes by PPAR-γ. Nature (2005) 437:759-763.
  • WELCH JS, RICOTE M, AKIYAMA TE, GONZALEZ FJ, GLASS CK: PPARγ and PPARΔ negatively regulate specific subsets of lipopolysaccharide and IFNγ target genes in macrophages. Proc. Natl. Acad. Sci. USA (2003) 100:6712-6717.
  • LI M, PASCUAL G, GLASS CK: Peroxisome proliferator-activated receptor dependent repression of the inducible nitric oxide synthase gene. Mol. Cell Biol. (2000) 20:4699-4707.
  • ZAVARONI I, SRDIGO D, ZUCCARELLI A et al.: Insulin resistance/compensatory hyperinsulinemia predict carotid intimal medial thickness in patients with essential hypertension. Nutr. Metab. Cardiovasc. Dis. (2006) 16(1):22-27.
  • DEFRONZO RA, JACOT E, JEQUIER E, MAEDER E, WAHREN J, FELBER JP: The effect of insulin on the disposal of intravenous glucose. Diabetes (1981) 30:1000-1007.
  • EXTON JH, MALLETTE LE, JEFFERSON LS et al.: The hormonal control of hepatic gluconeogenesis. Recent Prog. Horm. Res. (1970) 26:411-461.
  • COPPACK SW, JENSEN MD, MILES JM: In vivo regulation of lipolysis in humans. J. Lipid Res. (1994) 35(2):177-193.
  • SHI H, KOKOEVA MV, INOUYE K, TZAMELI I, YIN H, FLIER JS: TLR4 links innate immunity and fatty acid-induced insulin resistance. J. Clin. Invest. (2006) 116(11):3015-3025.
  • LIANG CP, HAN S, OKAMOTO H et al.: Increased CD36 protein as a response to defective insulin signaling in macrophages. J. Clin. Invest. (2004) 113(5):764-773.
  • HAN S, LIANG CP, DEVRIES-SEIMON T et al.: Macrophage insulin receptor deficiency increases ER stress-induced apoptosis and necrotic core formation in advanced atherosclerotic lesions. Cell Metab. (2006) 3(4):257-266.
  • LIANG CP, HAN S, SENOKUCHI T, TALL AR: The macrophage at the crossroads of insulin resistance and atherosclerosis. Circ. Res. (2007) 100(11):1546-1555.
  • ODEGAARD JI, RICARDO-GONZALEZ RR, GOFORTH MH et al.: Macrophage-specific PPARγ controls alternative activation and improves insulin resistance. Nature (2007) 447:1116-1120.
  • BABAEV V, YANCEY PG, RYZHOV SV et al.: Conditional knockout of macrophage PPARγ increases atherosclerosis in C57BL/6 and low-density lipoprotein receptor deficient mice. Arterioscler. Thromb. Vasc. Biol. (2005) 25:1647-1653.
  • GREGOR MG, HOTAMISLIGIL G: Adipocyte stress: the endoplasmic reticulum and metabolic disease. J. Lipid Res. (2007) 48(9):1905-1914.
  • BAUMGARTL J, BAUDLER S, SCHERNER M et al.: Myeloid lineage cell-restricted insulin resistance protects apolipoproteinE-deficient mice against atherosclerosis. Cell Metab. (2006) 3:247-256.
  • HOTAMISLIGIL GS, SHARGILL NS, SPIEGELMAN BM: Adipose expression of TNF-α: direct role in obesity-linked insulin resistance. Science (1993) 259:87-91.
  • SELL H, DIETZE-SCHROEDER D, ECKEL J: The adipocyte-myocyte axis in insulin resistance. Trends Endocrinol. Metab. (2006) 17(10):416-422.
  • CHEN HONG: Cellular inflammatory responses: novel insights for obesity and insulin resistance. Pharmacol. Res. (2006) 53:469-477.
  • FAIN JN, CHEEMA PS, BAHOUTH SW, LLOYD HILER M: Resistin release by human adipose tissue explants in primary culture. Biochem. Biophys. Res. Commun. (2003) 300:674-678.
  • RAJALA MW, LIN Y, RANALLETTA M et al.: Cell type-specific expression and coregulation of murine resistin and resistin-like molecule-α in adipose tissue. Mol. Endocrinol. (2002) 116:1920-1930.
  • MARSHALL LA, BOLOGNESE B, ROSHAK A: Characterization of phospholipase A2 release by elicited-peritoneal macrophage and its relationship to eicosanoid production. J. Lipid Mediat. Cell Signal. (1994) 10(3):295-313.
  • SARTIPY P, LOSKOTOFF DJ: Monocyte chemoattractant protein 1 in obesity and insulin resistance. Proc. Natl. Acad. Sci. USA (2003) 100:7265-7270.
  • DI GREGORIO GB, YAO-PORENGASSER A, RASOULI N et al.: Expression of CD68 and macrophage chemoattractant protein-1 genes in human adipose and muscle tissues. Diabetes (2005) 54:2305-2313.
  • CHRISTIANSEN T, RICHELSEN B, BRUUN JM: Monocyte chemoattractant protein-1 is produced in isolated adipocytes, associated with adiposity and reduced after weight loss in morbid obese subjects. Int. J. Obes. Relat. Metab. Disord. (2005) 29:146-150.
  • KANDA H, TATEYA S, TAMORI Y et al.: MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J. Clin. Invest. (2006) 116(6):1494-1505.
  • KAMEI N, TOBE K, SUZUCKI R et al.: Overexpression of monocyte chemoattractant protein-1 in adipose tissue causes macrophage recruitment and insulin resistance. J. Biol. Chem. (2006) 281(36):26602-26614.
  • WEISBERG SP, HUNTER D, HUBER R et al.: CCR2 modulates inflammatory and metabolic effects of high fat feeding. J. Clin. Invest. (2006) 116(1):115-124.
  • TSOU C-L, PETERS W, SI Y et al.: Critical roles for CCR2 and MCP-3 in monocyte mobilization from bone marrow and recruitment to inflammatory sites. J. Clin. Invest. (2007) 117(4):902-909.
  • CHEN A, MUMICK S, ZHANG C et al.: Diet induction of monocyte chemoattractant protein-1 and its impact on obesity. Obes. Res. (2005) 13(8):1311-1320.
  • INOUYE KE, SHI H, HOWARD JK et al.: Absence of CC chemokine ligand 2 does not limit obesity-associated infiltration of macrophages. Diabetes (2007) 56(9):2242-2250.
  • GORDON S, TAYLOR PR: Monocyte and macrophage heterogeneity. Nat. Rev. (2005) 5:953-964.
  • LUMENG CN, BODZIN JL, SALTIEL AR: Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J. Clin. Invest. (2007) 117(1):175-184.
  • ZEYDA M, FARMER D, TODORIC J et al.: Human adipose tissue macrophages are of an anti-inflammatory phenotype but capable of excessive pro-inflammatory mediator production. Int. J. Obes. (2007) 31:1420-1428.
  • GORDON S: Alternative activation of macrophages. Nat. Rev. Immunol. (2003) 3:23-25.
  • MOSSER DM: The many faces of macrophage activation. J. Leukoc. Biol. (2003) 73:209-212.
  • HUANG H, PAUL WE: Impaired interleukin 4 signaling in T helper type 1 cells. J. Exp. Med. (1998) 187(8):1305-1313.
  • WURSTER AL, WITHERS DJ, UCHIDA T, WHITE MF, GRUSBY MJ: Stat6 and IRS-2 cooperate in interleukin 4 (IL-4)-induced proliferation and differentiation but are dispensable for IL-4 dependent rescue from apoptosis. Mol. Cell Biol. (2002) 22(1):117-126.
  • CUNARD R, ETO Y, MULJADI JT, GLASS CK, KELLY CJ, RICOTE M: Repression of IFN-γ expression by peroxisome proliferator-activated receptor γ. J. Immunol. (2004) 172:7530-7536.
  • WOHLFERT EA, NICHOLS FC, NEVIUS E, CLARK RB: Peroxisome proliferator-activated receptor γ (PPARγ) and immunoregulation: enhancement of regulatory T cells through PPARγ-dependent and -independent mechanisms. J. Immunol. (2007) 178:4129-4135.
  • VATS D, MUKUNDAN L, ODEGAARD JI et al.: Oxidative metabolism and PGC-1β attenuate macrophage-mediated inflammation. Cell Metab. (2006) 4:13-24.
  • SOLINAS G, VILCU C, NEELS J et al.: JNK in macrophages plays a key role in the development of obesity-induced insulin resistance. Cell Metab. (In Press).
  • DETAEYE BM, NOVITSKAYA T, MCGUINNESS OP et al.: Macrophage TNF-α contributes to insulin resistance and hepatic steatosis in diet-induced obesity. Am. J. Physiol. (2007) 293(3):E713-E725.
  • CASTELEIJN E, KUIPER J, VAN ROOJ HCJ, KAMPS JAAM, KOSTER JF, VAN BERKEL TJC: Hormonal control of glycogenolysis in paranchymal liver cells by kupffer and endothelial liver cells. J. Biol. Chem. (1988) 263:2699-2703.
  • LUMENG CN, DEYOUNG SM, SALTIEL AR: Macrophages block insulin action in adipocytes by altering expression of signaling and glucose transport proteins. Am. J. Physiol. Endocrinol. Metab. (2007) 292:E166-E174.
  • BOUHLEL MA, DERUDAS B, RIGAMONTI E et al.: PPARγ activation primes human moncytes into alternative M2 macrophages with anti-inflammatory properties. Cell Metab. (2007) 6:137-143.
  • TORRES AH, DE SANCTIS JB, DE BRICENO M, HERNANDEZ N, FINOL HJ: Inflammation and nitric oxide production in skeletal muscle of Type 2 diabetic patients. J. Endocrinol. (2004) 181:419-427.
  • BRUN JM, HELGE JW, RICHELSON B, STALLKNECHT B: Diet and exercise reduce low-grade inflammation and macrophage infiltration in adipose tissue but not in skeletal muscle in severely obese subjects. Am. J. Physiol. Endocrinol. Metab. (2005) 290:E961-E967.
  • LECLERCQ IA, MORAIS ADSM, SCHROYEN B, HUL NV, GEERTS A: Insulin resistance in hepatocytes and sinusoidal liver cells: mechanisms and consequences. J. Hepatol. (2007) 47:142-156.
  • HUNDAL RS, PETERSON KF, MAYERSON AB et al.: Mechanism by which high-dose aspirin improves glucose metabolism in Type 2 diabetes. J. Clin. Invest. (2002) 109(10):1321-1326.
  • BUTLER AE, JANSON J, BONNER-WEIR S, RITZEL R, RIZZA RA, BUTLER PA: β-cell deficit and increased β-cell apoptosis in humans with Type 2 diabetes. Diabetes (2003) 52:102-110.
  • BELL GI, POLONSKY KS: Diabetes mellitus and genetically programmed defects in β-cell function. Nature (2001) 414:788-791.
  • MAEDLER K, SCHUMANN DM, SAUTER N et al.: Low concentration of interleukin-1 β induces FLICE-inhibitory protein-mediated β cell proliferation in human pancreatic islets. Diabetes (2006) 55(10):2713-2722.
  • MAEDLER K: β cells in Type 2 diabetes – a crucial contribution to pathogenesis. Diabetes Obes. Metab. (2007) (Epub April 19).
  • PATEL L, BUCKELS AC, KINGHORN IJ et al.: Resistin is expressed in human macrophages and is directly regulated by PPARγ activators. Biochem. Biophys. Res. Comm. (2003) 300:472-476.
  • BODELS AM, VARMA V, YAO-BORENGASSER A et al.: Pioglitazone induces apoptosis of macrophages in human adipose tissue. J. Lipid Res. (2006) 47:2080-2088.
  • GELMAN L, FEIGE JN, DESVERGNE B: Molecular basis of selective PPARγ modulation for the treatment of Type 2 diabetes. Biochim. Biophys. Acta (2007) 1771(8):1094-1107.
  • LIU K, BLACK RM, ACTON JJ et al.: Selective PPARγ modulators with improved pharmacological profiles. Bioorg. Med. Chem. Lett. (2005) 15:2437-2440.
  • LESNIEWSKI LA, HOSCH SE, NEELS JG et al.: Bone marrow-specific CAP gene deletion protects against high-fat diet-induced insulin resistance. Nat. Med. (2007) 13:455-462.
  • HEVENER AL, OLEFSKY JM, REICHART D et al.: Macrophage PPARg is required for normal skeletal muscle and hepatic insulin sensitivity and full antidiabetic effects of thiazolidinediones. J. Clin. Invest. (2007) 117:1658-1669.
  • DE TAEGE BM, NOVITSKAYA T, MCGUINNESS OP et al.: Macrophage TNF-α contributes to insulin resistance and hepatic steatosis in diet-induced obesity. Am. J. Physiol. Endocrinol. Metab. (2007) 293:E713-E725.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.